DEVELOPMENTAL FUNDS

财务基金 要求提供470 000美元的发展资金，以支持联合国儿童基金会的试点项目倡议， 转化研究（320，000美元）和癌症项目的突出优点，被评为第20位以上 NIH研究部分的百分位数（15万美元）。2007年，该中心实施了这些举措。 在过去的供资期间，由于预算原因，CCSG发展资金每年仅限于147，806美元。 最后一场比赛后的限制。2005年3月任命中心主任后， 决定在该中心的研究项目完成之前，不会授予这类资金。 重新组织并审查和批准中心成员资格。截至本报告提交之时， 共计591 224美元已转入2007年7月至2008年6月的无费用延长期，用于 支持针对具体方案的试点项目。 在本项目期内，通过试验项目机制推动新的研究项目， 联合国儿童基金会利用总额为170万美元的慈善基金资助了31名现任或前任联合国儿童基金会成员。年度项目 供资为35 000至50 000美元，为期一至两年。Richard Baer，PhD，基础副总监 研究，监督中心的试点项目倡议。他负责组织和选择广告 特设委员会成员根据资助机会的主题，并确保严格的 使用NIH评分系统的科学评论。 在项目期间，由慈善基金支助的选定试点项目包括： 肿瘤抑制因子ARC在有丝分裂中的表征，Y. Mao（CGE） 结果：Zhang，J.，艾哈迈德，S.，毛，Y.，05 The Famous Women（2007） 染色体排列J Cell Biol 178：773-784. 基因组去甲基化在乳腺癌中的机制和后果，T.比利时（CGE） 结果：NIH R 01赠款基于规划阶段的试点数据。 <$干细胞和癌症干细胞在小鼠乳腺，A Efstratiadis（BC） 结果：初步数据是2007年5月在同一标题下的“工作研究”的基础， 哥伦比亚科技风险投资公司和默克公司。 剖析T-ALL中的致癌途径：逆转录病毒诱变和人类T细胞淋巴母细胞白血病， A Ferrando（LDM） 成果：正在编写两份手稿 肿瘤细胞分化和增殖中的抑制环螺旋转录因子，A lavarone（CSN） 结果：NIH/NCI R 01 CA 85628 Id 2在细胞周期调控和癌症中的作用$230，000/year，8/1/2006- 7/31/2011 干细胞和表皮肿瘤的发生，D欧文斯（CGE） 结果：皮肤病基金会资助，表皮干细胞作为皮肤肿瘤的靶点 55，000美元/年，2006年7月1日至2007年6月30日 神经胶质瘤肿瘤血管生成中的Id 2蛋白，A Lasorella（CSN） 结局：Lasorella A.，Stegmuller J.，Guardavaccaro D.，刘G，Carro M.S.，罗斯柴尔德G.，德拉托雷- Ubieta L.，Pagano M.，Bonni A.，Lavarone A.，后期促进复合物对Id 2的降解 偶联细胞周期退出和轴突生长。Nature，422：471-474，2006 在项目期间收到试点项目资金的其他区域协调委员会成员包括： R. Baer，K.船员J.戈蒂埃，D赫什曼和K约瑟夫，（公元前）; A乔和I B温斯坦，（PCD）;和MB特里 和T Liu（CE），W. Gu（CSN和BC）和J Kandel（PC）。 2007年，该委员会的高级领导小组商定了以下供资机制，以促进内部和外部环境， 跨学科转化研究： 教科文组织协调委员会特定方案试点基金，以促进方案内的转化研究 举措七个研究项目和正在发展的神经肿瘤学项目中的每一个都被分配给 70 000美元，用于在竞争基础上资助一个对《公约》的转化目标具有战略意义的试点项目， 节目资助机会已经公布，获奖者将在10月中旬选出。 方案间试点项目基金，以促进方案间翻译 研究倡议。该委员会将分配给每个项目4万美元，在竞争的基础上， 涉及两个项目的项目，优先考虑涉及以下项目的项目 两个不同的区域，即，基础、疾病特异性或人口科学。机构和慈善基金 将支持区域协调委员会方案间试点项目倡议。融资机会已 将于10月中旬公布并选出获奖者 2007年夏天，联合国儿童基金会发起了桥梁奖（BrAwa），以支持 首次申请时，NIH研究部门将其评为第20百分位以上的突出优点，或 竞争性续延，但由于预算限制而没有得到资助。CICC桥接奖将 每年在竞争基础上资助两个75 000美元的项目。关于这一融资机会的通知已经 并将于2007年12月提供资金。

DEVELOPMENTAL FUNDS Developmental funds, $470,000, are requested to support HICCC pilot project initiatives that foster translational research, ($320,000) and cancer projects of outstanding merit that were rated above the 20th percentile by an NIH study section ($150,000). These Center initiatives were implemented by the SLT in 2007. Over the past funding period CCSG Development funds were limited to $147,806 per year due to budgetary constraints following the last competition. Following the appointment of the Center Director in March 2005, it was decided that funds in this category would not be awarded until the Center's research programs were reorganized and Center membership reviewed and approved. At the time of this submission, the accumulated total, $591,224, has been carried over to the no-cost extension period, July 2007 - June 2008, to be used in support of program-specific pilot projects. To promote novel research initiatives through the pilot project mechanism during the current project period, HICCC utilized philanthropic funds totaling $1.7M to fund 31 current or former HICCC members. Annual project funding was $35,000 to $50,000 for one to two years. Richard Baer, PhD, Associate Director for Basic Research, oversees the Center's pilot project initiatives. He is responsible for organizing and selecting the ad hoc committee members based on the subject matter of the funding opportunity and ensuring rigorous scientific review using the NIH scoring system. Selected pilot projects supported by philanthropic funds during the project period include: ¿ Characterization of the tumor suppressor ARC in mitosis, Y. Mao (CGE) Outcome: Zhang, J., Ahmad, S., Mao, Y., (2007) BubRland APC/EB1 cooperate to maintain metaphase chromosome alignment. J Cell Biol 178: 773-784. ¿ Mechanisms and consequences of genome demethylation in mammary carcinoma, T. Bestor (CGE) Outcome: NIH R01 grant based on pilot data in planning stages. ¿ Stem cells and cancer stem cells in mouse mammary glands, A Efstratiadis (BC) Outcome: Preliminary data was the basis for a May 2007 "Work Study" under the same title between Columbia Science & Technology Ventures and Merck. ¿ Dissecting oncogenic pathways in T-ALL: retroviral mutagenesis and human T-cell lymphoblastic leukemia, A Ferrando (LDM) Outcome: two manuscripts in preparation ¿ Helix loop helix transcription factors in differentiation and proliferation of tumor cells, A lavarone (CSN) Outcome: NIH/NCI R01CA85628 Id2 in cell cycle regulation and cancer $230,000/year, 8/1/2006- 7/31/2011 ¿ Stem cells and the genesis of epidermal tumors, D Owens (CGE) Outcome: Dermatology Foundation grant, Epiderma stem cells as targets for cutaneous neoplasia $55,000/year, 7/1/2006-6/30/2007 ¿ Id2 protein in glioma tumor angiogenesis, A Lasorella (CSN) Outcome: Lasorella A., Stegmuller J., Guardavaccaro D., Liu G., Carro M.S., Rothschild G., de la Torre- Ubieta L., Pagano M., Bonni A., lavarone A., Degradation of Id2 by the anaphase promoting complex couples cell cycle exit and axonal growth. Nature, 422:471-474, 2006 Other HICCC members who received pilot project funds during the project period include: R. Baer, K. Crew J. Gautier, D Hershman, and K Joseph, (BC); A Joe and I B Weinstein, (PCD); and MB Terry and T Liu (CE), W. Gu (CSN and BC), and J Kandel (PC). In 2007, the HICCC's senior leadership team agreed on the following funding mechanisms to promote intraand inter-programmatic translational research: HICCC Program-specific Pilot (PROspe) Fund to stimulate intra-programmatic translational research initiatives. Each of the seven research programs and the developing Neuro-oncology program are assigned $70,000 to fund, on a competitive basis, a pilot project of strategic relevance to the translational goals of the program. Funding opportunities have been announced and awardees will be selected by mid October. ¿ HICCC Inter-programmatic (InterPro) Pilot Project Fund to stimulate inter-programmatic translational research initiatives. The HICCC will assign to each program $40,000 to fund, on a competitive basis, a pilot project that involves Pis from two programs, with priority given to those projects involving programs from two distinct areas, i.e., basic, disease-specific, or population science. Institutional and philanthropic funds will support the HICCC inter-programmatic pilot project initiative. Funding opportunities have been announced and awardees will be selected by mid-October ¿ In the summer of 2007, the HICCC initiated the Bridging Award (BrAwa) to support cancer projects of outstanding merit that were rated above the 20th percentile by an NIH study section as a first application or competitive renewal but were not funded due to budgetary restrictions. The HICCC Bridging Award will fund annually, on a competitive basis, two $75,000 projects. Notices of this funding opportunity have been announced and funding will be awarded in December 2007.